PROPYLENE GLYCOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C3H8O2
Molecular Weight	76.0944
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

CC(O)CO

InChI

InChIKey=DNIAPMSPPWPWGF-UHFFFAOYSA-N

InChI=1S/C3H8O2/c1-3(5)2-4/h3-5H,2H2,1H3

HIDE SMILES / InChI

Molecular Formula	C3H8O2
Molecular Weight	76.0944
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description

PROPYLENE GLYCOL is a component of SYSTANE® Lubricant. It is used for the temporary relief of burning and irritation due to dryness of the eye.

Approval Year

Conditions

Conditions

Condition	Modality	Targets	Highest Phase	Product
Dryness of the eye 1	Palliative		Approved 8,429	SYSTANE LUBRICANT

C_max

Value	Dose	Co-administered	Analyte	Population
0.8 mg/mL	20.7 mg 3 times / day steady-state, oral		PROPYLENE GLYCOL plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
3.23 mg × h/mL	20.7 mg 3 times / day steady-state, oral		PROPYLENE GLYCOL plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
3.79 h	20.7 mg 3 times / day steady-state, oral		PROPYLENE GLYCOL plasma	Homo sapiens

Doses

Show entries

Dose	Population	Adverse events
0.8 g/kg 1 times / day multiple, oral (mean)	unhealthy, 13 years n = 1	Other AEs: Distributive shock, Acidosis metabolic...
20.7 g 3 times / day multiple, oral	unhealthy, 18 - 65 years n = 16	Other AEs: Mental disorder NOS...
41.4 g 2 times / day multiple, oral	unhealthy, 18 - 65 years n = 6	Other AEs: Mental disorder NOS...
8.64 g single, rectal	healthy, adult n = 10
173 mg/kg single, rectal	healthy, children n = 4

Showing 1 to 5 of 5 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Acidosis metabolic		0.8 g/kg 1 times / day multiple, oral (mean)	unhealthy, 13 years n = 1
Distributive shock		0.8 g/kg 1 times / day multiple, oral (mean)	unhealthy, 13 years n = 1
Mental disorder NOS	severe, 1 patient	20.7 g 3 times / day multiple, oral	unhealthy, 18 - 65 years n = 16
Mental disorder NOS	severe, 2 patients	41.4 g 2 times / day multiple, oral	unhealthy, 18 - 65 years n = 6

Showing 1 to 4 of 4 entries

Previous1Next

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP2E1 882 CYP1A2 1,524

Drug as perpetrator

Show entries

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2E1 970	inhibitor 3,277	likely		yes (co-administration study)
CYP1A2 1,692	inhibitor 3,277	no

Showing 1 to 2 of 2 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY20330	https://www.001chemical.com/chem/4254-14-2
001 Chemical	DY554323	https://www.001chemical.com/chem/4254-15-3
001 Chemical	DY561043	https://www.001chemical.com/chem/57-55-6
3B Scientific (Wuhan) Corp	3B4-0065	http://www.3bsc.com/index/pro_info.php?id=17913
3B Scientific (Wuhan) Corp	3B4-0066	http://www.3bsc.com/index/pro_info.php?id=17914

Showing 1 to 5 of 104 entries

Previous1 2 3 4 5…21Next

PubMed

Show entries

Title	Date	PubMed
Endothelial dysfunction is an independent factor responsible for vasospastic angina.	2001 Dec	11724660
Metal-catalyzed oxidation of human growth hormone: modulation by solvent-induced changes of protein conformation.	2001 Jan	11064379
A new colorimetric assay for studying and rapid screening of membrane penetration enhancers.	2001 Jul	11496953
Analysis of pesticide residues in wine by solid-phase extraction and gas chromatography with electron capture and nitrogen-phosphorus detection.	2001 Jun 1	11459301
Flow-mediated, endothelium-dependent vasodilatation is impaired in male body builders taking anabolic-androgenic steroids.	2001 Oct	11583730